Analysis of human nasal mucosal cell sheets fabricated using transported tissue and blood specimens
Analysis of human nasal mucosal cell sheets fabricated using transported tissue and blood specimens
复制标题
DOI：
10.1016/j.reth.2019.05.001
复制
发表时间：
2019-12-01
影响因子：
4.3
通讯作者：
Kojima, Hiromi
中科院分区：
文献类型：
--
作者：
Kasai, Yoshiyuki;Morino, Tsunetaro;Kojima, Hiromi
在此之前，我们成功地将自体鼻粘膜细胞片移植到5名接受中耳炎切除术的患者的中耳中，这在临床环境中防止了中耳炎的复发。目前人类细胞培养的良好生产规范（GMP）标准要求建立细胞处理中心（CPC），作为无菌设施。然而，由于在每个医院建立和维护这种设施的实际困难，人们认为需要一个功能性的运输系统来继续有效的再生治疗。在本研究中，从3名人类志愿者中获得的鼻粘膜组织和自体血液运输超过3小时。使用角质形成细胞培养基培养消毒的鼻组织，所述角质形成细胞培养基包括从血液制备的自体血清。24天后，培养的鼻粘膜细胞运输超过3小时，随后评估细胞数量，活力和纯度。此外，我们还分析了CK4、CK8和CK18这些鼻粘膜细胞片用于中耳再生治疗的适用性。总之，我们证实了可以使用运输的鼻粘膜组织和血液来制造鼻粘膜细胞片。这项研究将有助于建立一种新的再生疗法的临床应用，伴随着公司和医院之间的运输。(C)2019年，日本再生医学学会。制作和主办：Elsevier B.V.
Previously, we succeeded in transplanting autologous nasal mucosal cell sheets in the middle ears of 5 patients, who underwent cholesteatoma resection, which prevents recurrence of cholesteatoma in clinical settings. Current good manufacturing practice (GMP) standards for human cell cultivation requires the establishment of cell processing centers (CPC) which act as germ-free facilities. However, due to practical difficulties involved in establishing and maintaining such facilities at each individual hospital, a functional transport system is felt to be needed for the continuation of effective regenerative therapy. In the current study, nasal mucosal tissue and autologous blood obtained from 3 human volunteers were transported for over 3 h. Disinfected nasal tissues were cultured using keratinocyte culture medium, which included autologous serum prepared from blood. After 24 d, cultured nasal mucosal cells were transported for over 3 h and subsequently assessed for cell number, viability and purity. Moreover, CK4, CK8, and CK18 were analyzed the suitability of these nasal mucosal cell sheets for middle ear regenerative therapy.Overall, we confirmed that nasal mucosal cell sheets can be fabricated using transported nasal mucosal tissue and blood. This study would be contribute to establish a new regenerative therapy for clinical application, accompanied with transportation between companies and hospitals. (C) 2019, The Japanese Society for Regenerative Medicine. Production and hosting by Elsevier B.V.